Phase 1/2 Trial Confirms Safety With Repeated Dosing Supporting Further Development in Early-stage Disease and Combination Treatment Settings ATLANTA, GA - December 8, 2025 (NEWMEDIAWIRE) - GeoVax ...

Patent Protects Novel Application of Gedeptin Therapy Across Multiple Solid Tumor Types; Supports Expansion of Gedeptin ...

The first-line standard of care for HR-positive/HER2-negative breast cancer is cyclin-dependent kinase (CDK)4/6 inhibitors ...

The U.S. FDA assigned a target action date of April 8, 2026PRINCETON, N.J.--(BUSINESS WIRE)--$BMY #FDA--Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA ...

Axatilimab showed a consistent safety profile in cGVHD patients, with no new safety signals and a decrease in TEAEs over time. The AGAVE-201 trial led to FDA approval of axatilimab at 0.3 mg/kg every ...

The global bioconjugation market is projected to grow at an estimated CAGR of close to 13% over the next five years. This growth is fueled by the rising need for targeted therapies, continuous ...

Researchers led by the Institut Pasteur, Université Paris, have developed a vaccine that elicits anti-Immunoglobulin E ...

Coherus Oncology, Inc. (NASDAQ: CHRS) today announced compelling six-year overall survival (OS) follow-up results from the Phase 3 JUPITER-02 trial evaluating LOQTORZI® (toripalimab-tpzi) plus ...

An Institute for Value-Based Medicine ® event held in New Haven, Connecticut, on October 30, 2025, brought together a diverse ...

The addition of tucatinib to first-line trastuzumab plus pertuzumab delayed disease progression among a cohort of women with ...

In the analyses, 68% percent of patients received prior CHOP-based therapy, 35% had salvage chemotherapy, 20% had autologous stem cell transplant, 17% had an HDAC inhibitor, and 38% had prior exposure ...

Chemotherapy-free approaches could offer comparable efficacy with less toxicity ORLANDO, Fla., Dec. 7, 2025 /PRNewswire/ -- ...